Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring Chimerism and Treatment Strategies in Beta Thalassemia Major
NCT03101423Unknown
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Aug 2016
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Open-label trial of aldesleukin and donor regulatory T lymphocytes in beta thalassemia major (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Chimerism rate monitored by STR-PCR at 3 months. Status: unknown.
02
Drugs
aldesleukindonor regulatory T lymphocytes
03
Conditions
beta thalassemia major
Beyond the preview
Go deeper on NCT03101423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101423.